Questo infatti è quello che ho trovato anche nello studio che è segnalato nella homepage, di cui in quel caso si riporta peraltro solo un minimo estratto... ho trovato qualcosina di più qui...
Citazione:Androgenetic alopecia, also known male pattern baldness, occurs not only in men but also in women. Current treatments such as minoxidil (1, Rogaine®, a potassium channel opener) and finasteride (2,Propecia®, a 5a-reductase inhibitor) are only efficacious in a small percentage of subjects. Novel mechanisms with robust efficacy and long-term safety are still needed for the treatment of androgenetic alopecia.
Thyroid hormone receptor agonists (thyromimetics) are closely associated with hair growth. Topical triiodothyronine (T3, 3) stimulates epidermal proliferation, dermal thickening, and hair growth in both mice and rats.1 Some human subjects given with thyroxine (T4, 4) to treat thyroid hormone deficiency reported hair growth as a side effect. Thyroid hormones are also found to directly alter human hair follicle functions including anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation.2 Thyroid receptors (TR) interact with hairless gene product (Hr), a transcription factor required for hair growth and thyroid hormone receptor b1 is expressed in the human hair follicles.3 Recently, human female hair follicles were found to be a direct, nonclassical target for thyroid-stimulating hormone.4 However, use of oral thyroxine or thyroid hormones to
treat androgenetic alopecia is impractical due to their known cardiotoxicity. Therefore, we sought thyromimetics that are active topically and yet devoid of systemic pharmacological activities to avoid deleterious side effects. We set out to find soft drugs with high systemic clearance as indicated by pharmacokinetic (PK) data such as short-half life in human liver microsome (HLM) and fast hepatic clearance.
da qui a farne un topico, sperimentarlo in VIVO ecc ce ne passa....
Intanto che non venga in mente a nessuno di prendersi T3....![]
Citazione:Androgenetic alopecia, also known male pattern baldness, occurs not only in men but also in women. Current treatments such as minoxidil (1, Rogaine®, a potassium channel opener) and finasteride (2,Propecia®, a 5a-reductase inhibitor) are only efficacious in a small percentage of subjects. Novel mechanisms with robust efficacy and long-term safety are still needed for the treatment of androgenetic alopecia.
Thyroid hormone receptor agonists (thyromimetics) are closely associated with hair growth. Topical triiodothyronine (T3, 3) stimulates epidermal proliferation, dermal thickening, and hair growth in both mice and rats.1 Some human subjects given with thyroxine (T4, 4) to treat thyroid hormone deficiency reported hair growth as a side effect. Thyroid hormones are also found to directly alter human hair follicle functions including anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation.2 Thyroid receptors (TR) interact with hairless gene product (Hr), a transcription factor required for hair growth and thyroid hormone receptor b1 is expressed in the human hair follicles.3 Recently, human female hair follicles were found to be a direct, nonclassical target for thyroid-stimulating hormone.4 However, use of oral thyroxine or thyroid hormones to
treat androgenetic alopecia is impractical due to their known cardiotoxicity. Therefore, we sought thyromimetics that are active topically and yet devoid of systemic pharmacological activities to avoid deleterious side effects. We set out to find soft drugs with high systemic clearance as indicated by pharmacokinetic (PK) data such as short-half life in human liver microsome (HLM) and fast hepatic clearance.
da qui a farne un topico, sperimentarlo in VIVO ecc ce ne passa....
Intanto che non venga in mente a nessuno di prendersi T3....![]